Hill-Rom Hits New 52-Week High: What's Driving The Stock?
Zacks Investment Research | Jan 02, 2020 10:59PM ET
Shares of Hill-Rom Holdings, Inc. (NYSE:HRC) reached a new 52-week high of $114.97 on Jan 2, closing the session marginally lower at $113.74. The stock has rallied 5.6% since its third-quarter earnings announcement on Nov 1.
The company’s strong third-quarter results, backed by robust Patient Support Systems and global revenue growth, prompted this uptrend.
Let us delve deeper.
Q3 Performance
Hill-Rom exited fiscal 2019 on a strong note with better-than-expected results. The company saw a solid year-over-year increase in revenues on robust domestic growth, driven by sturdy performances in Patient Support Systems. Internationally, Asia Pacific, Latin America and EMEA registered strong revenue growth.
Hill-Rom is upbeat about continuing with the recent trend in the EMEA and the Asia Pacific, aided by a robust improvement in revenues on balanced growth across its segments and all geographies.
Other Key Drivers
Acquisitions: Hill-Rom has been steadily working toward acquisitions to accelerate growth across five key clinical focus areas, such as advancing patient mobility, wound care and prevention, surgical, safety and efficiency, clinical workflow solutions as well as respiratory help. The buyout of Voalte continues to reap benefits for Hill-Rom. In August 2019, the company announced the buyout of Breath Technologies, a developer and manufacturer of a patented nasal cannula technology that enables improved patient mobility. This latest takeover bodes well for Hill-Rom through fiscal 2020 as well.
Product Portfolio: Of late, the company is focusing on expansion through product development as reflected in higher research and development expenditure, which buoys optimism. The contribution from new products gave a significant boost to the top line in fiscal 2019. Hill-Rom recently introduced various products like RetinaVue 700 Imager, EarlySense and WatchCare. It expects to register long-lasting growth in the upcoming quarters with strong pipeline of products.
Digital Health Space: Investors are upbeat about Hill-Rom’s recently launched smartphone application, Linq mobile. This integrated Clinical Workflows with Nurse Call and clinical surveillance with monitoring systems, which facilitated team communication as well as efficiency. The company has also partnered with Microsoft (NASDAQ:MSFT) as a strategic step toward boosting its position in the Digital Health space. This alliance is further expected to contribute to the company’s top line through fiscal 2020.
Get The News You Want
Zacks Rank & Key Picks
Currently, Hill-Rom carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Haemonetics Corporation (NYSE:HAE) , Vapotherm, Inc (NYSE:VAPO) and Medtronic plc (NYSE:MDT) .
Haemonetics has a Zacks Rank #1 (Strong Buy) and a projected long-term earnings growth rate of 13.5%. You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.